stockrow
Saturday 7 November 2026
Export GRCE’s income statement to Excel — free account
Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
- EPS
- −333.3%
- Free cash flow
- −78.9%
Quarter to June 2026, against a year earlier
1.86
0.08
+4.49%
Follow GRCE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jun ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | — | — | — | — | — | 0 | — | 5 | 5 | 44 | +200.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 61.22 | — | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (8) | (17) | (39) | (26) | (20) | (10) | (52) | (15) | (13) | (9) | (22) | +1.9% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (10,039.80) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (8) | (17) | (39) | (26) | (20) | (10) | (42) | (13) | (10) | (8) | (20) | (0.2%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.66) | (46.05) | (34.07) | (14.48) | (8.16) | (1.62) | (5.70) | (1.35) | (0.79) | (0.47) | (1.18) | (3.7%) | ||||||
| Cash flow | (0.47) | (26.81) | (21.91) | (13.02) | (5.79) | (2.81) | (2.14) | (1.29) | (1.23) | (0.54) | (0.60) | +1.5% | ||||||
| Capex | 0.00 | (0.97) | (0.47) | (0.18) | (0.03) | 0.00 | (0.68) | (0.68) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.47) | (27.79) | (22.38) | (13.20) | (5.82) | (2.81) | (2.82) | (1.97) | (1.23) | (0.54) | (0.60) | +1.5% | ||||||
| Book value | 1.47 | 17.61 | 9.76 | 7.37 | 22.52 | 17.63 | 9.14 | 6.48 | 5.51 | 3.87 | 2.79 | +11.4% | ||||||
| Shares, m | 11 | 0 | 1 | 2 | 2 | 6 | 7 | 10 | 12 | 17 | 17 | +4.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | 356.47 | — | — | — | — | — | 160.85 | — | ||||||
| P/B | — | — | — | — | 1.28 | — | — | — | — | — | 0.67 | — | ||||||
| EV/Sales | — | — | — | — | 66.48 | — | — | — | — | — | 106.08 | — | ||||||
| EV/FCF | — | — | — | — | (0.92) | — | — | — | — | — | (2.08) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (5) | (10) | (25) | (23) | (14) | (17) | (16) | (12) | (15) | (9) | (10) | +6.1% | |||||
| Capex | (2) | 0 | (1) | 0 | 0 | — | (5) | (6) | — | — | 0 | +18.9% | ||||||
| Free cash flow | (5) | (10) | (25) | (23) | (14) | (17) | (21) | (19) | (15) | (9) | (10) | +6.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 6 | 2 | 14 | 11 | 61 | 42 | 26 | 22 | 21 | 15 | 13 | +10.8% | |||||
| Net debt | (6) | (5) | (24) | (14) | (61) | (44) | (28) | (23) | (22) | (17) | (14) | +11.7% | ||||||
| Shareholders’ equity | 16 | 6 | 11 | 13 | 56 | 108 | 68 | 62 | 67 | 64 | 48 | +16.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (40.36) | (90.69) | (143.65) | (85.40) | (46.13) | (10.28) | (40.85) | (16.86) | (13.17) | (11.24) | (33.74) | +29.1 pt | |||||
| ROIC | 0.00 | (763.15) | 0.00 | 0.00 | 0.00 | (15.08) | (81.36) | (20.74) | (23.44) | (14.76) | (43.36) | (14.8) pt | ||||||
| ROE | (47.44) | (147.88) | (450.89) | (212.26) | (57.33) | (11.98) | (48.15) | (19.82) | (14.91) | (11.94) | (36.19) | +35.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 15 | 24 | 28 | 32 | — | — | — | 4 | 6 | 5 | — | (11.5%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2021 · latest quarter Mar 2021 · fundamentals updated 2 Nov 2026
Grace Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HYPD Hyperion DeFi, Inc. | $39.8M | — (loss-making) | 0.5× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| DWTX Dogwood Therapeutics, Inc | $39.8M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| EXOZ eXoZymes Inc. | $38.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | Compare |
| IBO Impact Biomedical Inc. | $38.0M | — (loss-making) | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | Compare |
| ELTX Elicio Therapeutics, Inc. | $37.9M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRCE Grace Therapeutics, Inc. | $37.5M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | |
| ALDX Aldeyra Therapeutics, Inc. | $37.2M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| Median of peers | $38.0M | — | — | −55.27% | — | +9.54% | 66.67% | 0.00% |
Pay and ownership Proxy statement filed 28 July 2026
Ownership
Directors and executive officers, together
10.84%
Shore Pharma LLC
11.60%
Nantahala Capital Management, LLC
9.99%
ADAR1 Capital Management, LLC
9.99%
SS Pharma LLC
8.31%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement